Adp53 (Gendicine) 12 Years in Clinic – The First Approved Gene Therapy Product for CancerZhang, Wei-WeiMary Ann Liebert2018DOI 10.1089/hum.2017.218
Enhancement of Adenoviral Mediated P53 (Adp53) Tumor Killing with Amifostine Induced CDC2 Kinase ActivationStephen G. SwisherElsevier Science2000DOI 10.1016/s1072-7515(00)00650-5
Thermosensitized Effects of Adenovirus-mediated p53 (Adp53): Preclinical Study and a Phase II Clinical Trial in ChinaZHANG, SHAN-WENThermal Medicine(Japanese Journal of Hyperthermic Oncology)2003DOI 10.3191/thermalmedicine.19.141
A Phase I Study of Adp53 (INGN 201; ADVEXIN) for Patients with Platinum- and Paclitaxel-resistant Epithelial Ovarian CancerJudith K WolfElsevier Science2004DOI 10.1016/j.ygyno.2004.05.041
71 The Oncolytic Adenovirus ADP53DPR Replicates Selectively in P53 Altered Tumor Cells and Potential Tumor Spectrum Is Not Limited by the P73 StatusF. KuehnelElsevier Science2006DOI 10.1016/s0168-8278(06)80072-3
43 The P53-selective Oncolytic Adenovirus Adp53dpR Does Not Replicate in Primary Human Hepatocytes but Efficiently Lyses P53-altered Tumors in Vitro and in VivoJournal of HepatologyJournal of Hepatology2005DOI 10.1016/s0168-8278(05)81455-2
337 THE ONCOLYTIC ADENOVIRUS ADP53-SENSOR FOR SELECTIVE REPLICATION IN P53-ALTERED TUMORS AND POTENTIAL TARGET SPECTRUM IS NOT LIMITED BY THE P73 STATUSF. KuehnelElsevier Science2008DOI 10.1016/s0168-8278(08)60339-6